EUCTR2018-004581-34-ES进行中（未招募）1 期
An open-label Phase IV trial to evaluate the immunogenicity and safety of Diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated) and Haemophilus influenzae type b (DTaP-IPV-HB-Hib) conjugate vaccine (adsorbed) in preterm infants
Fundación Instituto Hispalense de Pediatría0 个研究点目标入组 140 人开始时间: 2019年1月22日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 140
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Preterm infants born between 24 (+0 days) – 36 (+6 days) weeks (42-90 days) (mean gestational age ± standard deviation, 31.05 ± 3.45 weeks) of gestation.
- •Subjects whose parents or legal guardians be able and wish to comply with all protocol requirements.
- •-Male or female children 6 to 12 (42-90 days) weeks of age at first vaccine.
- •-Written informed consent provided by the patient’s parents or legal guardians.
- •-Healthy subjects according the investigator criteria prior to the enrolling in the trial.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 140
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Foster children (male or female)
- •Receipt of any investigational product (drug or vaccine) within 30 days before the first dose of study vaccine or planned during the trial period.
- •Prolonged administration (defined as a total period of over 14 days) of immunosuppressive or other immunomodulatory drugs since the birth. In case of corticoids, this implies = 0.5 mg/kg/day prednisone dose or equivalent. Inhaled or topic steroids will be allowed.
- •During the study period, simultaneous participation in another trial in which the subject have received or will be expected to receive investigational or non experimental product (pharmaceutical product or medical device).
- •Taking in account the clinical history and physical exam, any known or suspected status of immunosuppression or immunodeficiency.
- •Family history of congenital or inherited immunodeficiency.
- •History of reaction or hypersensibility probably exacerbated by any of the vaccine components.
- •Major congenital defects or serious chronic diseases, including Kawasaki syndrome.
- •History of severe neurologic damage or seizures, including both disorders and episodes of hypotension or hypo-responsiveness, encephalopathies or any type of convulsions (febrile and afebrile).
- •Episode of apnea (cessation of respiration > 20s) within 7 days before vaccination.
- •Acute disease and/or fever at recruitment in the study.
- •?Fever is defined as a temperature = 37.5ºC (oral or axial temperature) or = 38.0º C (rectal temperature).
- •?Subjects with mild diseases (such us mild diarrhea or mild upper respiratory tract infection) without fever could be recruited at physician discretion.
- •History of any immunoglobulin therapy and/or blood product since the birth or scheduled administration during the trial.
- •History of diphtheria, tetanus, pertussis, hepatitis B, polio and Hib vaccination or disease.
- •Any disease which in the opinion of the investigator would interfere with the evaluation of the objectives of the study.
研究者
相似试验
进行中（未招募）
不适用
Study on the evaluation of the short-term and long-term response to the anti-flu vaccination Inflexal V in elderly patientsEUCTR2011-003188-31-ITCRUCELL SWITZERLAND AG
进行中（未招募）
不适用
Open Phase IV Clinical Study to Evaluate the Immunogenicity and Safety of a Rapid Immunization Schedule with FSME-IMMUN 0.25ml JUNIOR in Healthy Children aged 1 to below 15 Years - Pediatric Rapid TBE Immunization StudyEvaluation of Immunogenicity of a TBE (Tick Borne Encephalitis) Vaccine in previously unvaccinated children aged 1 to below 15 yearsMedDRA version: 12.1Level: LLTClassification code 10043847Term: Tick-borne viral encephalitisEUCTR2010-020097-42-ATBaxter Innovations GmbH240
进行中（未招募）
1 期
Open Phase IV Clinical Study to Evaluate the Immunogenicity and Safety of a Rapid Immunization Schedule with FSME-IMMUN 0.25 ml JUNIOR in Healthy Children aged 3 - 15 YearsPrevention of Tick-born encephalitis (TBE). The rapid immunization schedule recommended in the current SPC for FSME-IMMUN 0.5 ml (Day 0, Day 14) has been used in Austria for 20 years. FSME-IMMUN 0.25 ml was first administered in clinical trials in the year 2001 and the rapid immunization schedule is recommended for children ranging 1 to 16 years of age. However, limited data on immunogenicity when using the rapid immunization schedule in children exist.MedDRA version: 9.1Level: LLTClassification code 10043847Term: Tick-borne viral encephalitisEUCTR2007-000810-35-CZBIOVOMED300
进行中（未招募）
1 期
A Phase IV, randomised study to evaluate the immune responses of UK adolescent girls receiving Cervarix(TM) or Gardasil(TM) Human Papillomavirus vaccines - RCT of immune response in UK adolescent girls to HPV vaccinesThis study will investigate vaccines that prevent premalignant cervical lesions and cervical cancer causally related to Human Papillomavirus (HPV) types 16 and 18. This study will investigate whether immunisation against infection with HPV 16 and 18 may impact on other oncogenic HPV types, through cross-protection.MedDRA version: 9.1 Level: LLT Classification code 10058580 Term: Human papilloma virus serology testEUCTR2008-006773-32-GBHealth Protection Agency84
进行中（未招募）
不适用
A Phase IV, randomised study to evaluate the immune response of UK infants receiving DTaP/Hib/IPV, meningococcal C conjugate and pneumococcal conjugate vaccines, antibody persistence and responses to booster doses in the second year of life. (code: Sched2) - Sched2All products arre vaccines and are given to healthy volunteers to induce immunological responses to provide protection against:Pediacel - tetanus, diphtheria, polio, pertussis (whooping cough), Haemophilus influenza ttype b (Hib disease)Menjugate and Nies-VacC - meningococcal C diseasePrevenar - pneumococcal diseaseMedDRA version: 9.1Level: PTClassification code 10027274Term: Meningococcal infectionMedDRA version: 9.1Level: LLTClassification code 10061353Term: Pneumococcal infectionMedDRA version: 9.1Level: LLTClassification code 10013023Term: DiphtheriaMedDRA version: 9.1Level: LLTClassification code 10043376Term: TetanusMedDRA version: 9.1Level: LLTClassification code 10034738Term: PertussisMedDRA version: 9.1Level: LLTClassification code 10018955Term: Haemophilus meningitisMedDRA version: 9.1Level: LLTClassification code 10036008Term: PolioEUCTR2007-004056-36-GBHealth Protection Agency